Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Part of paid clinical trials in Miami, Florida.

Sponsor
Foundation for the National Institutes of Health
Study ID
NCT07122700
Status
Recruiting
Apply to this trial

Conditions

  • Cirrhosis, Liver
  • Liver Fat
  • Liver Fibrosis
  • Liver Inflammation
  • Liver Steatoses
  • Metabolic Associated Fatty Liver Disease
  • Metabolic Associated Steatotic Liver Disease
  • NASH

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Study Details

The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.

Key Dates

Start date
May 13, 2025
Status verified
Aug 2025
Primary completion
Jun 30, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
400 participants (estimated)

Primary Outcome Measure

Detection of At-Risk MASH [ Time Frame: within 120 days of study enrollment. ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Clinical Pharmacology of MiamiMiamiFlorida33172
Alexander Prezioso, MD
[email protected]
305-320-1164
Ohio Clinical TrialsColumbusOhio43212
Angela Eakin
[email protected]
614-754-7679
First Surgical HospitalBellaireTexas77401
Daveshvari Solanki
[email protected]
210-253-7778
Endeavor Clinical TrialsSan AntonioTexas78240
Emanuel De Noia, MD
[email protected]
210-305-5771

Find similar trials in Miami, FL

By research site
Clinical Pharmacology of Miami· Miami, FLOhio Clinical Trials· Columbus, OHFirst Surgical Hospital· Bellaire, TXEndeavor Clinical Trials· San Antonio, TX

Related Studies